BRAF and non-small cell lung carcinoma: Within NSCLC, there were no gene alterations that were significantly enriched in primary tumors, irrespective of BRAF mutation Class, but all three classes of BRAF mutant metastatic NSCLC tumors were enriched for TP53 mutations (p < 0.0001) (Figure 2G–I).